RESUMEN
Duchenne muscular dystrophy (DMD) is a genetic disorder caused by loss of the protein dystrophin. In humans, DMD has early onset, causes developmental delays, muscle necrosis, loss of ambulation, and death. Current animal models have been challenged by their inability to model the early onset and severity of the disease. It remains unresolved whether increased sarcoplasmic calcium observed in dystrophic muscles follows or leads the mechanical insults caused by the muscle's disrupted contractile machinery. This knowledge has important implications for patients, as potential physiotherapeutic treatments may either help or exacerbate symptoms, depending on how dystrophic muscles differ from healthy ones. Recently we showed how burrowing dystrophic (dys-1) C. elegans recapitulate many salient phenotypes of DMD, including loss of mobility and muscle necrosis. Here, we report that dys-1 worms display early pathogenesis, including dysregulated sarcoplasmic calcium and increased lethality. Sarcoplasmic calcium dysregulation in dys-1 worms precedes overt structural phenotypes (e.g., mitochondrial, and contractile machinery damage) and can be mitigated by reducing calmodulin expression. To learn how dystrophic musculature responds to altered physical activity, we cultivated dys-1 animals in environments requiring high intensity or high frequency of muscle exertion during locomotion. We find that several muscular parameters (e.g., size) improve with increased activity. However, longevity in dystrophic animals was negatively associated with muscular exertion, regardless of effort duration. The high degree of phenotypic conservation between dystrophic worms and humans provides a unique opportunity to gain insight into the pathology of the disease as well as the initial assessment of potential treatment strategies.
Asunto(s)
Distrofia Muscular Animal/terapia , Distrofia Muscular de Duchenne/terapia , Condicionamiento Físico Animal , Esfuerzo Físico/fisiología , Animales , Caenorhabditis elegans/genética , Caenorhabditis elegans/fisiología , Proteínas de Caenorhabditis elegans/genética , Modelos Animales de Enfermedad , Humanos , Ratones , Ratones Endogámicos mdx , Contracción Muscular/fisiología , Músculo Esquelético/crecimiento & desarrollo , Músculo Esquelético/fisiopatología , Distrofia Muscular Animal/genética , Distrofia Muscular Animal/fisiopatología , Distrofia Muscular de Duchenne/genética , Distrofia Muscular de Duchenne/fisiopatología , Esfuerzo Físico/genéticaRESUMEN
5-S-L-Cysteinyl-L-dopa is a well-known pigment intermediate and analysis of its serum concentration is well suited for evaluation of treatment and follow-up of stage III and IV malignant melanoma. A simplified analytical method is described using organic extraction followed by clean-up on a boronate gel to capture the compound containing vicinal hydroxyls. Weak acid solution elutes the 5-S-cysteinyldopa suitable for high-performance liquid chromatography (HPLC). The absolute recoveries of cysteinyldopa and its diastereomer 5-S-D-cysteinyl-L-dopa (used as an internal standard) were 81.5 +/- 2.8% and 81.3 +/- 2.7%, respectively, and use of the internal standard for the whole procedure gave an analytical recovery of 101 +/- 0.8%. The limit of quantitation was 1.5 nmol/L and the imprecision of the method was < 5.0% over the analytical range 1.5-500 nmol/L. The method is cheap and easy to perform and compares well with other described techniques. The use of the method is illustrated by results obtained during treatment of a patient with metastatic malignant melanoma.
Asunto(s)
Química Clínica/métodos , Cisteinildopa/sangre , Anciano , Cromatografía Líquida de Alta Presión , Humanos , Melanoma/sangre , Melanoma/secundario , Reproducibilidad de los Resultados , Neoplasias Cutáneas/sangre , Neoplasias Cutáneas/patologíaRESUMEN
PURPOSE: Glutathione is an important cellular compound which affects detoxification of electrophiles and may have direct or indirect effects on pigment formation. It is therefore of importance to study interstitial concentrations in melanoma tissue while decreasing its formation with an enzyme inhibitor and increasing its amount with cysteine deliverers. METHOD: Glutathione formation was inhibited by intraperitoneal (i.p.) injection of BSO. N-Acetylcysteine (NAC) and l-2-oxothiazolidine-4-carboxylate (OTC) were then given i.p. to subgroups of the animals. Intratumoral microdialysis was performed during BSO treatment, during BSO treatment combined with NAC or OTC and after discontinuation of BSO but ongoing NAC or OTC treatment. RESULTS: Glutathione formation was inhibited during BSO treatment. The dialysate concentrations of both glutathione and cysteine decreased during concomitant treatment with BSO and NAC or OTC. Recovery of the amounts of the two compounds was seen in both groups after discontinuation of BSO treatment. In the NAC group we also observed an acute increase in dialysate concentrations of cysteine after NAC injection. The 5-S-cysteinyldopa concentrations were unaffected by variations in glutathione and cysteine concentrations. CONCLUSIONS: 5-S-Cysteinyldopa in melanoma is not formed from glutathione in vivo to any appreciable extent. The intracellular amount of cysteine is probably not a limiting factor for cysteinyldopa formation. It seems that both NAC and OTC can be used as cysteine deliverers to melanoma cells in vivo to produce recovery of glutathione levels after synthesis inhibition by BSO treatment.
Asunto(s)
Acetilcisteína/farmacología , Cisteína/metabolismo , Glutatión/metabolismo , Melanoma/metabolismo , Tiazoles/farmacología , Acetilcisteína/metabolismo , Animales , Butionina Sulfoximina/farmacología , Cisteína/efectos de los fármacos , Cisteinildopa/efectos de los fármacos , Cisteinildopa/metabolismo , Inhibidores Enzimáticos/farmacología , Glutatión/efectos de los fármacos , Humanos , Melanoma/patología , Melanoma Experimental/metabolismo , Melanoma Experimental/patología , Ratones , Ratones Desnudos , Microdiálisis , Trasplante de Neoplasias , Precursores de Proteínas/metabolismo , Ácido Pirrolidona Carboxílico , Tiazoles/metabolismo , Tiazolidinas , Trasplante Heterólogo , Células Tumorales CultivadasRESUMEN
BACKGROUND: Intravenous and subcutaneous microdialysis was performed to compare the free concentrations and pharmacokinetics of L-3, 4-dihyroxyphenylalanine (L-dopa) in blood and tissue in healthy subjects and in patients with Parkinson disease. METHODS: Nine healthy volunteers and 10 patients with Parkinson disease, stage 1. 5-2 according to the Hoehn-Yahr rating scale, took part of the study. In the patient group subcutaneous microdialysis and ordinary blood sampling were performed, whereas in the control group intravenous microdialysis was also performed. Microdialysis samples were collected in fractions of 15 min. The first two fractions were collected for analysis of basal concentrations. A blood sample was also taken. The patients were then given one tablet of Madopar((R)) (100 mg of L-dopa and 25 mg of benserazide), and the microdialysis was continued for another 210 min. Blood samples were obtained at 30-min intervals. RESULTS: The serum samples gave a significantly higher mean area under the curve (AUC; 491 +/- 139 micromol. min/L) than that for intravenous dialysates (235 +/- 55.3 micromol. min/L), suggesting a protein binding of 50%. The L-dopa concentrations from the subcutaneous dialysates matched those from the intravenous dialysates, indicating rapid distribution of L-dopa to the tissues. CONCLUSIONS: Parkinsonian patients in early stages of the disease have a pharmacokinetic pattern of free L-dopa similar to that of healthy subjects. Comparison of AUCs from microdialysis with ordinary serum analysis revealed data indicating significant protein binding. Microdialysis is a suitable and easily applied tool in pharmacokinetic studies.
Asunto(s)
Dihidroxifenilalanina/farmacocinética , Dopaminérgicos/farmacocinética , Adulto , Anciano , Cromatografía Líquida de Alta Presión , Soluciones para Diálisis/metabolismo , Dihidroxifenilalanina/sangre , Dihidroxifenilalanina/uso terapéutico , Dopaminérgicos/sangre , Dopaminérgicos/uso terapéutico , Femenino , Humanos , Masculino , Microdiálisis/métodos , Persona de Mediana EdadRESUMEN
OBJECTIVES: The pharmacokinetics of free L-dopa in blood and tissue of five parkinsonian patients with malignant melanoma was studied with microdialysis. In one case the effect of L-dopa treatment on 5-S-cysteinyldopa and the melanoma was studied. Gastric emptying and its effects on free L-dopa in blood were also investigated in one of the patients. METHODS: Five patients were given 100 mg L-dopa with 25 mg benserazide. Blood and dialysates from the circulation and fatty tissue were collected for analysis. [13C]-Octanoic breath test was used for analyzing gastric half-emptying time. RESULTS: Four of the patients had similar pharmacokinetic patterns for L-dopa and a significant (P < 0.05) increase of serum 5-S-cysteinyldopa occurring 30 min after L-dopa intake. Delayed L-dopa peaks and slow gastric half-emptying time were found in 1 patient. A dose-dependent increase of 5-S-cysteinyldopa occurred but no melanoma metastases were seen during long-term L-dopa therapy. CONCLUSION: L-dopa therapy increases 5-S-cysteinyldopa levels but does not seem to cause progress of melanomas. Gastric emptying impacts L-dopa pharmacokinetics.
Asunto(s)
Levodopa/farmacocinética , Melanoma/complicaciones , Enfermedad de Parkinson/tratamiento farmacológico , Neoplasias Cutáneas/complicaciones , Anciano , Antiparkinsonianos/farmacocinética , Antiparkinsonianos/uso terapéutico , Benserazida/farmacocinética , Benserazida/uso terapéutico , Femenino , Humanos , Levodopa/uso terapéutico , Masculino , Microdiálisis , Persona de Mediana Edad , Enfermedad de Parkinson/complicacionesRESUMEN
Using microdialysis of human melanoma transplants in athymic mice we have shown that interstitial glutathione levels decreased during treatment with buthionine sulphoximine (BSO) and recovered after cessation of treatment. The cysteine concentrations also decreased, while 5-S-cysteinyldopa tended to increase during BSO treatment. Restoration of the glutathione levels was not seen after either N-acetylcysteine (NAC) or L-2-oxothiazolidine-4-carboxylate (OTC) injections, given on the third day of BSO treatment. These results were to be expected since NAC and OTC were given during the BSO treatment, and BSO is a specific and potent inhibitor of glutathione synthesis. Cysteine levels, however, increased after the NAC injection but remained unaltered after the OTC injection, while 5-S-cysteinyldopa remained unaltered after both the NAC and the OTC injections.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacología , Butionina Sulfoximina/farmacología , Cisteína/metabolismo , Cisteinildopa/biosíntesis , Inhibidores Enzimáticos/farmacología , Glutatión/metabolismo , Melanoma/tratamiento farmacológico , Melanoma/metabolismo , Acetilcisteína/farmacología , Animales , Cisteinildopa/metabolismo , Interacciones Farmacológicas , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Microdiálisis , Trasplante de Neoplasias , Ácido Pirrolidona Carboxílico , Tiazoles/farmacología , TiazolidinasRESUMEN
The use of a wide variety of materials in the construction of maxillofacial prostheses makes biocompatibility testing a necessity. However, the dental literature contains few reports of biocompatibility testing of maxillofacial prosthetic materials. The cytotoxic profiles of five room-temperature cross-linking (RTC)-silicone elastomers were investigated by means of two in vitro cell culture techniques. Mouse fibroblast cells (L929) were used, and the results indicated that RTC-silicone elastomers adversely affected cells in culture and that storage of samples for 1 week in saline solution did not alter this effect. Clinical follow-up of patients wearing prostheses made of these silicone materials is warranted to evaluate host reactions in long-term contact with human mucous membrane and skin tissue.